Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of romidepsin plus CHOP versus CHOP alone in previously untreated peripheral T-cell lymphoma
MOH_2017-07-30_000688Phase 3Not yet recruiting
- Sponsor
- LYSARC
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of romidepsin in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by LYSARC. Planned start May 2017; status: not yet recruiting.
02
Drugs
romidepsin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on MOH_2017-07-30_000688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-30_000688.